Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Augustine Asset Management Inc.

Augustine Asset Management Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 51,846 shares of the biopharmaceutical company’s stock after selling 1,436 shares during the period. Gilead Sciences accounts for 1.3% of Augustine Asset Management Inc.’s portfolio, making the stock its 14th biggest holding. Augustine Asset Management Inc.’s holdings in Gilead Sciences were worth $4,789,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. FMR LLC lifted its holdings in Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Gilead Sciences by 723.3% during the fourth quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock valued at $594,370,000 after purchasing an additional 5,653,075 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after buying an additional 1,793,145 shares in the last quarter. Finally, International Assets Investment Management LLC grew its position in Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after buying an additional 1,622,806 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 572,824 shares of company stock valued at $53,611,715. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock opened at $96.14 on Wednesday. The company has a market capitalization of $119.82 billion, a price-to-earnings ratio of 1,068.22, a P/E/G ratio of 1.25 and a beta of 0.18. The firm has a 50 day moving average of $93.07 and a two-hundred day moving average of $86.99. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $100.51.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Bank of America reissued a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Barclays increased their price target on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Piper Sandler boosted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a report on Monday, February 3rd. Finally, Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.